日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:

Five-Year Analysis of the JULIET Trial of Tisagenlecleucel in Patients With Relapsed/Refractory Large B-Cell Lymphoma

JULIET试验中Tisagenlecleucel治疗复发/难治性大B细胞淋巴瘤患者的五年分析

Maziarz, Richard T; Bishop, Michael R; Tam, Constantine S; Borchmann, Peter; Worel, Nina; McGuirk, Joseph P; Holte, Harald; Waller, Edmund K; Jaglowski, Samantha; Andreadis, Charalambos; Foley, Stephen Ronan; Westin, Jason R; Fleury, Isabelle; Ho, P Joy; Mielke, Stephan; Teshima, Takanori; Janakiram, Murali; Hsu, Jingmei; Izutsu, Koji; Kersten, Marie José; Ghosh, Monalisa; Wagner-Johnston, Nina; Kato, Koji; Corradini, Paolo; Ma, Wanying; Han, Xia; Nuortti, Marja; Awasthi, Rakesh; Mundt, Kirsten E; Majdan, Marta; Maier, Harald J; Jegerlehner, Andrea; Salles, Gilles; Schuster, Stephen J

Long-term follow-up of belumosudil as second or subsequent line of therapy for steroid-dependent/resistant cGVHD: clinical outcomes from a Japanese study

贝鲁莫舒地尔作为二线或后续治疗方案治疗激素依赖性/耐药性慢性移植物抗宿主病(cGVHD)的长期随访:一项日本研究的临床结果

Kato, Koji; Inamoto, Yoshihiro; Kawakita, Toshiro; Onishi, Yasushi; Matsuoka, Ken-Ichi; Shiratori, Soichi; Ikegame, Kazuhiro; Hiramoto, Nobuhiro; Toyosaki, Masako; Katayama, Yuta; Koga, Yuhki; Murayama, Shun; Sasagawa, Yuji; Shindo, Mami; Teshima, Takanori; Hatake, Kiyohiko; Maeda, Yoshinobu

Differences in Perspectives and Policies Regarding End-of-Life Care Between Hematologists and Gastroenterologists

血液科医生和胃肠病科医生在临终关怀方面的观点和政策差异

Matsunaga, Takuya; Murase, Kazuyuki; Hinotsu, Shiro; Takada, Kohichi; Teshima, Takanori; Sato, Ken; Nagaoka, Yasuhiro; Machino, Takayuki; Sugama, Yusuke; Kobune, Masayoshi; Ishitani, Kunihiko

Adenovirus-Associated Opsoclonus After Allogeneic Hematopoietic Stem Cell Transplantation

异基因造血干细胞移植后腺病毒相关性眼阵挛

Miyajima, Toru; Hoshino, Setsuaki; Nojima, Shingo; Shiratori, Souichi; Iwanami, Taishi; Teshima, Takanori

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study

鲁索替尼治疗皮质类固醇难治性或皮质类固醇依赖性慢性移植物抗宿主病患者:III期REACH3研究的3年最终分析

Zeiser, Robert; Russo, Domenico; Ram, Ron; Hashmi, Shahrukh K; Chakraverty, Ronjon; Middeke, Jan Moritz; Musso, Maurizio; Giebel, Sebastian; Uzay, Ant; Langmuir, Peter; Hamad, Nada; Burock, Karin; Gowda, Maanasa; Stefanelli, Tommaso; Lee, Stephanie J; Teshima, Takanori; Locatelli, Franco

Comparable outcomes with 14-, 21-, or standard 28-day venetoclax in the first cycle of azacitidine-venetoclax in untreated acute myeloid leukemia: real-world experience from the Hokkaido Leukemia Net

在未经治疗的急性髓系白血病患者中,阿扎胞苷-维奈克拉方案首个疗程中,采用14天、21天或标准28天维奈克拉治疗的疗效相当:来自北海道白血病网的真实世界经验

Kanaya, Minoru; Onozawa, Masahiro; Matsukawa, Toshihiro; Miyashita, Naoki; Fujii, Fumiaki; Yoshida, Shota; Nagai, Jun; Aiba, Masayuki; Hidaka, Daisuke; Hashiguchi, Junichi; Senjo, Hajime; Igarashi, Tetsuyuki; Chiba, Masahiro; Yamamoto, Satoshi; Shimizu, Taku; Ishio, Takashi; Yokoyama, Shota; Ebata, Ko; Iyama, Satoshi; Oyake, Tatsuo; Kondo, Takeshi; Teshima, Takanori

Refinement of day 28 treatment response criteria for acute GVHD: a collaboration study of the JSTCT and MAGIC

完善急性移植物抗宿主病(GVHD)第28天治疗反应标准:JSTCT和MAGIC的合作研究

Akahoshi, Yu; Inamoto, Yoshihiro; Spyrou, Nikolaos; Nakasone, Hideki; Diniz, Marcio A; Asada, Noboru; Ayuk, Francis; Choe, Hannah K; Doki, Noriko; Eto, Tetsuya; Etra, Aaron M; Hexner, Elizabeth O; Hiramoto, Nobuhiro; Hogan, William J; Holler, Ernst; Kataoka, Keisuke; Kawakita, Toshiro; Tanaka, Masatsugu; Tanaka, Takashi; Uchida, Naoyuki; Vasova, Ingrid; Yoshihara, Satoshi; Ishimaru, Fumihiko; Fukuda, Takahiro; Chen, Yi-Bin; Kanda, Junya; Nakamura, Ryotaro; Atsuta, Yoshiko; Ferrara, James L M; Kanda, Yoshinobu; Levine, John E; Teshima, Takanori

The impact of the SARS-CoV-2 pandemic on umbilical cord blood transplantation in Japan: insights from an interrupted time series analysis

SARS-CoV-2 大流行对日本脐带血移植的影响:基于中断时间序列分析的启示

Nakamura, Nobuhiko; Morishita, Tetsuji; Hayashi, Hiromi; Okabe, Motohito; Nakasone, Hideki; Uchida, Naoyuki; Doki, Noriko; Fukuda, Takahiro; Yoshihara, Satoshi; Tanaka, Masatsugu; Nishida, Tetsuya; Hasegawa, Yuta; Matsuoka, Ken-Ichi; Sawa, Masashi; Eto, Tetsuya; Onizuka, Makoto; Katayama, Yuta; Kato, Koji; Ishimaru, Fumihiko; Tabuchi, Ken; Atsuta, Yoshiko; Kanemura, Nobuhiro; Teshima, Takanori

CML With Mutant ASXL1 Showed Decreased Sensitivity to TKI Treatment via Upregulation of the ALOX5-BLTR Signaling Pathway.

携带突变型 ASXL1 的 CML 通过上调 ALOX5-BLTR 信号通路,对 TKI 治疗的敏感性降低

Miyashita Naoki, Onozawa Masahiro, Kasahara Kohei, Matsukawa Toshihiro, Onodera Yasuhito, Suzuki Kohjin, Takaku Tomoiku, Teshima Takanori, Kondo Takeshi

A comparative study of GVHD prophylaxis using low dose ATG versus PTCy for PBSCT based on two independent prospective cohorts

基于两个独立前瞻性队列的PBSCT中低剂量ATG与PTCy预防GVHD的比较研究

Shiratori, Souichi; Sugita, Junichi; Ishikawa, Jun; Kuroha, Takashi; Mori, Yasuo; Eto, Tetsuya; Kasahara, Senji; Fukushima, Kentaro; Harada, Mine; Teshima, Takanori